Search hospitals > Washington > Bremerton
Harrison HealthPartners Hematology and Oncology-Bremerton
Claim this profileBremerton, Washington 98310
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
215 reported clinical trials
1 medical researcher
Summary
Harrison HealthPartners Hematology and Oncology-Bremerton is a medical facility located in Bremerton, Washington. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Harrison HealthPartners Hematology and Oncology-Bremerton is involved with conducting 215 clinical trials across 399 conditions. There are 1 research doctors associated with this hospital, such as Richard L. Deming.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Clinical Trials running at Harrison HealthPartners Hematology and Oncology-Bremerton
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Cancer
Bladder Carcinoma
Anal Cancer
Squamous Cell Carcinoma
Multiple Myeloma
Urothelial Carcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Harrison HealthPartners Hematology and Oncology-Bremerton?
Harrison HealthPartners Hematology and Oncology-Bremerton is a medical facility located in Bremerton, Washington. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Harrison HealthPartners Hematology and Oncology-Bremerton is involved with conducting 215 clinical trials across 399 conditions. There are 1 research doctors associated with this hospital, such as Richard L. Deming.